Analysis Based on the Simplified Sequence Component Method

分析了对称分量存在不足,结合平衡线路的模变换数学特性,得出简化序分量法在输电线路的故障分析原理。提出了简化序分量法在短路和断线故障分析及选相原理,解决了距离保护作为yd变压器远后备保护存在的问题。On the basis of an analysis of the disadvantages of symmetrical component,under consideration of mathematical characteristics of the modular transformation of a balance line,this paper obtains the principle of application of the simplified sequence component method for fault analysis on the power transmission line.It further discusses the principle of application of the simplified sequence component method in short-circuit and open-circuit fault analysis and phase selection,and solves existing problems in using distance protection as distant backup protection for Yd transformers

Analysis on the Current Phase Compensation in Differential Protection for Transformer

分析了接线双绕组变压器微机差动保护相位补偿采用角接与算法相位补偿关系,变压器差动保护内部两相短路故障灵敏度与相位补偿关系,得出无论变压器中性点是否接地,相位补偿选择低压侧的方案对差动保护灵敏度有利。This paper analyzes the relationship between angle-connection phase compensation and the algorithm phase compensation using in the current phase compensation in differential protection forWiring two-winding transformer microcomputer,and the relationship between the two phase short circuit fault sensitivity and phase compensation in differential protection for transformer,and then concludes that whether the transformer neutral point grounds or not,phase compensation choosing the plan of low voltage is good for the differential protection sensitivity

巢湖微囊藻和浮游甲壳动物昼夜垂直迁移的初步研究

2002年10月进行了巢湖微囊藻和几种优势浮游甲壳动物的昼夜垂直变化的研究,结果表明:微囊藻具有明显的昼夜垂直变化现象。白天上层水中的微囊藻密度显著高于下层水中,夜晚逐渐下沉使得下层水中的密度相对高于上层水。微囊藻与叶绿素a、水温、溶解氧和pH等均呈显著的正相关(p<0.01)。几种优势浮游甲壳动物的昼夜垂直迁移存在较大的差异。短尾秀体溞和角突网纹溞白天在下层水(1.5m和2.5m)中的密度较高,夜晚则倾向于在上层水(0m和0.5m)中活动。相反,卵形盘肠溞白天在上层水中密度较高,象鼻溞则在11:00和

类泛素蛋白及其中文命名

泛素家族包括泛素及类泛素蛋白,约20种成员蛋白.近年来,泛素家族领域取得了迅猛发展,并已与生物学及医学研究的各个领域相互交叉.泛素家族介导的蛋白质降解和细胞自噬机制的发现分别于2004和2016年获得诺贝尔奖.但是,类泛素蛋白并没有统一规范的中文译名. 2018年4月9日在苏州召开的《泛素家族介导的蛋白质降解和细胞自噬》专著的编委会上,部分作者讨论了类泛素蛋白的中文命名问题,并在随后的\"泛素家族、自噬与疾病\"(Ubiquitinfamily,autophagy anddiseases)苏州会议上提出了类泛素蛋白中文翻译草案,此草案在参加该会议的国内学者及海外华人学者间取得了高度共识.冷泉港亚洲\"泛素家族、自噬与疾病\"苏州会议是由美国冷泉港实验室主办、两年一度、面向全球的英文会议.该会议在海内外华人学者中具有广泛影响,因此,参会华人学者的意见具有一定的代表性.本文介绍了10个类别的类泛素蛋白的中文命名,系统总结了它们的结构特点,并比较了参与各种类泛素化修饰的酶和它们的生物学功能.文章由45名从事该领域研究的专家合作撰写,其中包括中国工程院院士1名,相关学者4名,长江学者3名,国家杰出青年科学基金获得者18名和美国知名高校华人教授4名.他们绝大多数是参加编写即将由科学出版社出版的专著《泛素家族介导的蛋白质降解和细胞自噬》的专家

湖北4种木本植物新记录及资源现状

2017～2019年,我们在对湖北五峰后河国家级自然保护区进行本底资源调查过程中发现了若干新记录。本文对其中4种木本植物新记录进行报道,分别为乐东拟单性木兰[Parakmeria lotungensis(Chun&C.H. Tsoong) Y.W. Law]、乐昌含笑(Michelia chapensis Dandy)、峨眉鹅耳枥(Carpinus omeiensis H.H. Hu&D. Fang)和尾叶紫薇(Lagerstroemia caudata Chun&F.C. How ex S.K. Lee&L.F. Lau)。同时,我们也对这4种木本植物的种群现状、濒危状况和资源利用进行了调查,为进一步保护工作的开展提供了基础

洱海叶绿素a浓度的季节动态和空间分布

2010年5月至2011年4月，对洱海叶绿素a的季节动态、空间分布及其与环境因子的关系进行研究．结果表明，水体中叶绿素a浓度存在明显的季节变化，其变化范围为4．11～24．30μg／L，年平均值为10．4±6．5μg／L，最小值出现在2011年3月，最大值出现在2010年9月．叶绿素a浓度在夏、秋季较高，冬、春季较低．在空间变化上，叶绿素a浓度在南部湖区最大，其次是北部湖区，中部湖区最低．Pearson相关系数和主成分分析表明，洱海叶绿素a浓度在不同湖区中与水温和透明度均呈极显著相关．总氮在北部和南部湖区与叶绿素a浓度均存在一定的相关性，而总磷与叶绿素a浓度在南部湖区存在一定的相关性．根据修正的卡尔森营养状态指数，洱海综合TSI值为50．6，水质处于中营养状态

洱海叶绿素a浓度的季节动态和空间分布

2010年5月至2011年4月,对洱海叶绿素a的季节动态、空间分布及其与环境因子的关系进行研究.结果表明,水体中叶绿素a浓度存在明显的季节变化,其变化范围为4.11～24.30μg/L,年平均值为10.4±6.5μg/L,最小值出现在2011年3月,最大值出现在2010年9月.叶绿素a浓度在夏、秋季较高,冬、春季较低.在空间变化上,叶绿素a浓度在南部湖区最大,其次是北部湖区,中部湖区最低.Pearson相关系数和主成分分析表明,洱海叶绿素a浓度在不同湖区中与水温和透明度均呈极显著相关.总氮在北部和南部湖区与叶绿素a浓度均存在一定的相关性,而总磷与叶绿素a浓度在南部湖区存在一定的相关性.根据修正的卡尔森营养状态指数,洱海综合TSI值为50.6,水质处于中营养状态

社会转型与文化转型·海峡两岸圆桌论坛·实录

徐新建(四川大学教授、人类学高级论坛副秘书长):大家好。今天的话题围绕"文化转型"展开。据我所知这既是人类学圈的一个新提法,也是一个有争议的话题。我想请徐杰舜教授首先交代一下议题的来源和这次圆桌对话的意义。虽然在座有部分学者参与谋划了很久,但多数人是没有参与的。今天上午周大鸣教授做了简短的表态,强调提"文化转型"的目的是一种抗争,也就是人类学和社会学的抗争,后者提出的"社会转型"几乎主导了现实社会的思想和实践。我想,这已涉及了知识生产和学术政治,值得各位关注。下面就请徐杰舜老师做简要说明

Aripiprazole versus other atypical antipsychotics for schizophrenia

BACKGROUND: In most western industrialised countries, second generation (atypical) antipsychotics are recommended as first line drug treatments for people with schizophrenia. In this review we specifically examine how the efficacy and tolerability of one such agent - aripiprazole - differs from that of other comparable second generation antipsychotics. OBJECTIVES: To evaluate the effects of aripiprazole compared with other atypical antipsychotics for people with schizophrenia and schizophrenia-like psychoses. SEARCH METHODS: We searched the Cochrane Schizophrenia Group Trials Register (November 2011), inspected references of all identified studies for further trials, and contacted relevant pharmaceutical companies, drug approval agencies and authors of trials for additional information. SELECTION CRITERIA: We included all randomised clinical trials (RCTs) comparing aripiprazole (oral) with oral and parenteral forms of amisulpride, clozapine, olanzapine, quetiapine, risperidone, sertindole, ziprasidone or zotepine for people with schizophrenia or schizophrenia-like psychoses. DATA COLLECTION AND ANALYSIS: We extracted data independently. For dichotomous data we calculated risk ratios (RR) and their 95% confidence intervals (CI) on an intention-to-treat basis based on a random-effects model. Where possible, we calculated illustrative comparative risks for primary outcomes. For continuous data, we calculated mean differences (MD), again based on a random-effects model. We assessed risk of bias for each included study. MAIN RESULTS: We included 12 trials involving 6389 patients. Aripiprazole was compared to olanzapine, risperidone and ziprasidone. All trials were sponsored by an interested drug manufacturer. The overall number of participants leaving studies early was 30% to 40%, limiting validity (no differences between groups).When compared with olanzapine no differences were apparent for global state (no clinically important change: n = 703, 1 RCT, RR short-term 1.00 95% CI 0.81 to 1.22; n = 317, 1 RCT, RR medium-term 1.08 95% CI 0.95 to 1.22) but mental state tended to favour olanzapine (n = 1360, 3 RCTs, MD total Positive and Negative Syndrome Scale (PANSS) 4.68 95% CI 2.21 to 7.16). There was no significant difference in extrapyramidal symptoms (n = 529, 2 RCTs, RR 0.99 95% CI 0.62 to 1.59) but fewer in the aripiprazole group had increased cholesterol levels (n = 223, 1 RCT, RR 0.32 95% CI 0.19 to 0.54) or weight gain of 7% or more of total body weight (n = 1095, 3 RCTs, RR 0.39 95% CI 0.28 to 0.54).When compared with risperidone, aripiprazole showed no advantage in terms of global state (n = 384, 2 RCTs, RR no important improvement 1.14 95% CI 0.81 to 1.60) or mental state (n = 372, 2 RCTs, MD total PANSS 1.50 95% CI -2.96 to 5.96).One study compared aripiprazole with ziprasidone (n = 247) and both the groups reported similar change in the global state (n = 247, 1 RCT, MD average change in Clinical Global Impression-Severity (CGI-S) score -0.03 95% CI -0.28 to 0.22) and mental state (n = 247, 1 RCT, MD change PANSS -3.00 95% CI -7.29 to 1.29).When compared with any one of several new generation antipsychotic drugs the aripiprazole group showed improvement in global state in energy (n = 523, 1 RCT, RR 0.69 95% CI 0.56 to 0.84), mood (n = 523, 1 RCT, RR 0.77 95% CI 0.65 to 0.92), negative symptoms (n = 523, 1 RCT, RR 0.82 95% CI 0.68 to 0.99), somnolence (n = 523, 1 RCT, RR 0.80 95% CI 0.69 to 0.93) and weight gain (n = 523, 1 RCT, RR 0.84 95% CI 0.76 to 0.94). Significantly more people given aripiprazole reported symptoms of nausea (n = 2881, 3 RCTs, RR 3.13 95% CI 2.12 to 4.61) but weight gain (7% or more of total body weight) was less common in people allocated aripiprazole (n = 330, 1 RCT, RR 0.35 95% CI 0.19 to 0.64). Aripiprazole may have value in aggression but data are limited. This will be the focus of another review. AUTHORS' CONCLUSIONS: Information on all comparisons are of limited quality, are incomplete and problematic to apply clinically. Aripiprazole is an antipsychotic drug with a variant but not absent adverse effect profile. Long-term data are sparse and there is considerable scope for another update of this review as new data emerges from the many Chinese studies as well as from ongoing larger, independent pragmatic trials